Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response

• Massimiliano Bonifacio,
• Gianni Binotto,
• Elena Maino,
• Elisabetta Calistri,
• Luciana Marin,
• Luigi Scaffidi,
• Luca Frison,
• Federico De Marchi,
• Mauro Krampera,
• Giampiero Semenzato,
• Renato Fanin,
• Achille Ambrosetti,
• Mario Tiribelli

Affiliations

Massimiliano Bonifacio

Department of Medicine, Section of Hematology, University of Verona, Italy

Gianni Binotto

Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy

Elena Maino

Hematology Unit, Dell’Angelo Hospital, Venezia-Mestre, Italy

Elisabetta Calistri

Hematology Unit, Ca’ Foncello Hospital, Treviso, Italy

Luciana Marin

Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy

Luigi Scaffidi

Department of Medicine, Section of Hematology, University of Verona, Italy

Luca Frison

Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy

Federico De Marchi

Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy

Mauro Krampera

Department of Medicine, Section of Hematology, University of Verona, Italy

Giampiero Semenzato

Padua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy

Renato Fanin

Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy

Achille Ambrosetti

Department of Medicine, Section of Hematology, University of Verona, Italy

Mario Tiribelli

Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy